Tissue equivalent transplantation in the treatment of certain skin injuries

Chronic ulcers are a common and socially significant problem worldwide. Autodermoplasty is the gold standard treatment for chronic ulcers. However, it is not always possible to perform this surgical procedure for a rather large group of patients, due to some reasons, which include high risk of autodermotransplant rejection, lack of donor material, and patient’s unwillingness to undergo surgery with an often unpredictable result. A potential solution to the problem is to use skin equivalents from allogeneic donor material. The use of allogeneic (donor) human cells makes it possible to fill the deficit of the patient’s donor resources and close wound without causing additional injury to the patient. This paper provides an overview of the application of foreign and domestic biomedical cell products in clinical trials and real clinical practice. We draw conclusions on the efficiency of the considered biomedical cell products in the treatment of chronic ulcers, evaluate the conducted research, and make recommendations on the most efficient use of allogeneic dermatotropic biomedical cell products.

biomedical cell products, dermatotropic products, bioengineered constructs, skin equivalents, burns, diabetic ulcers, diabetic foot, multipotent mesenchymal stromal cells, keratinocytes

1. Agale SV. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013; 2013: 1–9.

2. Khrupkin VI, Zubritskiy VF, Ivashkin AN, Artem’ev AA, Fominykh EM. Dermatoplastika ranevykh defectov. M.: GEOTAR-Media, 2009: 192.

3. Ivashkin AN. Vosstanovlenie epitelial’nykh tkaney s ispolzovaniem kriokonservirovannykh zhiznesposobnykh dermotransplantatov i zhivogo ekvivalenta kozhi. [Dissertation]. М., 2009.

4. Snyder DL, Sullivan N, Schoelles KM. Technology Assessment Program Prepared for: Agency for Healthcare Research and Quality. Skin Substitutes for Treating Chronic Wounds. Technology Assessment Report: 540 Gaither Road Rockville, Maryland 20850 (FDA) (December 18, 2012).

5. Fedorov DN, Vasil’ev AV, Ivanov AA. Morfologicheskaya i immunogistokhimicheskaya kharakteristika reparativnykh protsessov v dlitel’no ne zazhivayushchikh ranakh. Arkhiv patologii. 2002; 1: 8–11.

6. Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJM. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. 2006; 117 (7S): 193–209.

7. Mat Saad AZ, Khoo TL, Halim AS. Wound bed preparation for chronic diabetic foot ulcers. ISRN Endocrinology. 2013; 1–9.

8. Karr JC. Bilayered skin-substitute technology for the treatment of diabetic foot ulcers: current insights. Chronic Wound Care Management and Research. 2017; 4: 7–16.

9. Loots MAM, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res. 1999; 291 (2–3): 93–9.

10. Terskikh VV, Vasil’ev AV, Rogovaya OS, Kiseleva EV, Dashinimaev EB, Ivashkin AN. Kletochniy implantat dlya vosstanovleniya defektov kozhnogo pokrova. RF Patent № 106528. 29.12.2010.

11. Kotslova AA, Binienko MA, Galileeva AN, Yudintseva NM, Sheyanov SD, Davydenko VV et al. Sravnitel’naya otsenka effektivnosti primeneniya ekvivalenta dermal’nogo pri neyropaticheskoy i neyroishemicheskoy formakh sindroma diabeticheskoy stopy. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2016; 20 (3): 62–71.

12. Kotslova AA, Binienko MA, Yudintseva NM, Blinova MI, Vlasov TD, Davydenko VV. Opyt primeneniya dermal’nogo ekvivalenta v kompleksnom lechenii sindroma diabeticheskoy stopy. Moskovskiy khirurgicheskiy zhurnal. 2016; 5 (51): 27–33.

13. Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 2018; 20 (11): 1401–1413.

14. Varkey M, Ding J, Tredget EE. Advances in skin substitutes – potential of tissue engineered skin for facilitating anti-fibrotic healing. Funct Biomater. 2015; 6 (3): 547–563.

15. Edmonds M. European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009; 8 (1): 11–18.

16. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Apligraf Diabetic Foot Ulcer Study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24 (2): 290–295.

17. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003; 26 (6): 1701–1705.

18. Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblastderived dermis. J Foot Ankle Surg. 2002; 41 (5): 291–299.

19. Lev-Tov H, Li CS, Dahle S, Isseroff RR. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial. Trials. 2013; 14 (1): 8.

20. Warriner RA, Cardinal M. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers. Adv Skin Wound Care. 2011; 24 (7): 306–311.

21. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996; 19 (4): 350–354.

22. Noordenbos J, Doré C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil. 1999; 20 (4): 275–281.

23. Ehrenreich M., Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006; 12 (9): 2407– 2424.

24. Still J, Glat P, Silverstein P, Griswold J, Mozingo D. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns. 2003; 29 (8): 837–841.

25. Santema TBK, Poyck PPC, Ubbink DT. Systematic review and meta-analysis of skin substitutes in the treatment of diabetic foot ulcers: Highlights of a Cochrane systematic review. Wound Repair Regen. 2016; 24 (4): 737–744.

26. Nathoo R, Howe N, Cohen G. Skin substitutes: an overview of the key players in wound management. J Clin Aesthet Dermatol. 2014; 7 (10): 44–48.

27. Garwood CS, Steinberg JS, Kim PJ. Bioengineered alternative tissues in diabetic wound healing. Clin Podiatr Med Surg. 2015; 32 (1): 121–133.